2089288-03-7
2089288-03-7
kg
2023-08-06
Custom Synthetic Chemicals,Biological Stains,Pharmaceutical Intermediates,Cosmetic Grade Chemicals,Enzyme,Nucleosides
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceATM Kinase Inhibitor AZD1390 is an orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. AZD1390 hypersensitizes tumors to chemo/radiotherapy. In addition, AZD1390 is able to cross the blood-brain barrier (BBB). ATM, a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of protein kinases, is upregulated in a variety of cancer cell types. It is activated in response to DNA double-strand breaks (DSB) and plays a key role in DNA repair.Basic Info
-
Product Name:
Unii-CI43qfe22O
Other Name:AZD1390;2089288-03-7;AZD-1390;UNII-CI43QFE22O;CI43QFE22O;CHEMBL4594429;SCHEMBL18631972;GTPL11277;EX-A2670;NSC803789
CAS No.:2089288-03-7
Molecular Formula:C27H32FN5O2
InChIKeys:VQSZIPCGAGVRRP-UHFFFAOYSA-N
Molecular Weight:477.6
Exact Mass:477.25400344
UNII:CI43QFE22O
NCI Thesaurus Code:C150167
Categories:
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Custom Synthetic Chemicals,Biological Stains,Pharmaceutical Intermediates,Cosmetic Grade Chemicals,Enzyme,Nucleosides
-
Location:
Room 308-80, building 1, 1963 Huaguan Road, Tianhe District, Guangzhou
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,100% TT in advance
-
Average lead Time:
30
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2021
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product